Potent and selective inhibitors of the calcium-activated potassium channel, kca3.1, for use as platform therapeutics

A compound of formula I:

• where:
• R1 is selected from H, halo, CF3, CN or NO2;
• R2 and R3 are independently selected from H, halo, CH3, CF3, CN or NO2;
• R4 is selected from H, halo, CN or CF3;
• R5 and R6 are independently selected from R9aC(O)O—, R9bOC(O)—, R9cC(O)NRd—, R9eR9fNC(O)—, or an alkyl ketone having from 1 to 10 carbon atoms, which carbon atoms are branched or unbranched and are unsubstituted or substituted by one of more substituents selected from halo, and NO2;
• R7 and R8 are independently selected from H, NR10aR10b, OR10c or C1 to C3 alkyl which is unsubstituted or substituted by one or more substituents selected from halo, or
• one of the pair of R5 and R7 or R6 and R8, together with the carbon atoms that they are attached to, form a 4- to 14-membered ring system that is carbocyclic or heterocyclic and which is unsubstituted or substituted by one or more substituents selected from halo, ═O, —OC(O)R10d, —(O)COR10e, and C1 to C6 alkyl;
• R9a to R9f and R10a to R10e are independently selected from H and C1 to C6 alkyl which is unsubstituted or substituted by one or more substituents selected from halo, or pharmaceutically acceptable salts and/or solvates thereof.